A
Andrew A Guirguis
Researcher at Broad Institute
Publications - 7
Citations - 322
Andrew A Guirguis is an academic researcher from Broad Institute. The author has contributed to research in topics: Ubiquitin ligase & Lenalidomide. The author has an hindex of 4, co-authored 5 publications receiving 122 citations. Previous affiliations of Andrew A Guirguis include Harvard University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Small molecule-induced polymerization triggers degradation of BCL6
Mikolaj Slabicki,Mikolaj Slabicki,Mikolaj Slabicki,Hojong Yoon,Jonas Koeppel,Jonas Koeppel,Jonas Koeppel,Lena Nitsch,Lena Nitsch,Lena Nitsch,Shourya S. Roy Burman,Cristina Di Genua,Cristina Di Genua,Katherine A. Donovan,Adam S. Sperling,Adam S. Sperling,Moritz Hunkeler,Jonathan M. Tsai,Jonathan M. Tsai,Rohan Sharma,Andrew A Guirguis,Andrew A Guirguis,Charles Zou,Priya Chudasama,Jessica A. Gasser,Jessica A. Gasser,Peter Miller,Peter Miller,Claudia Scholl,Stefan Fröhling,Radosław P. Nowak,Eric S. Fischer,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +34 more
TL;DR: The findings demonstrate that a small molecule can induce polymerization coupled to highly specific protein degradation, which in the case of BCL6 leads to superior pharmacological activity, creating new avenues for the development of therapeutics and synthetic biology.
Journal ArticleDOI
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Max Jan,Max Jan,Irene Scarfò,Rebecca C. Larson,Amanda Walker,Amanda Walker,Amanda Walker,Andrea Schmidts,Andrew A Guirguis,Andrew A Guirguis,Jessica A. Gasser,Jessica A. Gasser,Mikolaj Slabicki,Mikolaj Slabicki,Amanda A. Bouffard,Ana P. Castano,Michael Kann,Maria L. Cabral,Alexander Tepper,Alexander Tepper,Daniel E Grinshpun,Daniel E Grinshpun,Adam S. Sperling,Adam S. Sperling,Taeyoon Kyung,Quinlan L. Sievers,Michael E. Birnbaum,Marcela V. Maus,Marcela V. Maus,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +31 more
TL;DR: In this article, the authors developed ON and OFF switches for CAR T cells using the clinically approved drug lenalidomide, which mediates the proteasomal degradation of several target proteins by inducing interactions between the CRL4CRBN E3 ubiquitin ligase and a C2H2 zinc finger degron motif.
Journal ArticleDOI
CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.
Emma C. Fink,Emma C. Fink,Emma C. Fink,Marie McConkey,Marie McConkey,Marie McConkey,Dylan N. Adams,Dylan N. Adams,Dylan N. Adams,Saurav D. Haldar,Saurav D. Haldar,Saurav D. Haldar,James A. Kennedy,Andrew A Guirguis,Andrew A Guirguis,Andrew A Guirguis,Namrata D. Udeshi,D. R. Mani,Michelle C. Chen,Michelle C. Chen,Michelle C. Chen,Brian J. Liddicoat,Brian J. Liddicoat,Brian J. Liddicoat,Tanya Svinkina,Andrew T. Nguyen,Andrew T. Nguyen,Andrew T. Nguyen,Steven A. Carr,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +31 more
TL;DR: The Crbn I391V model is used to demonstrate that the in vivo therapeutic activity of lenalidomide in del(5q) myelodysplastic syndrome can be explained by heterozygous expression of Ck1α in del-5q cells, and to capture a major toxicity of this class of drugs.
Journal ArticleDOI
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
TL;DR: Lenalidomide and its related 'analogues' modulate the substrate specificity of the CRL4(CRBN) E3 ubiquitin ligase complex, may in time facilitate the degradation of other 'undruggable' proteins and allow for separation of detrimental side effects of IMiD compounds from those associated with therapeutic efficacy.
Journal ArticleDOI
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Aline Renneville,Aline Renneville,Aline Renneville,Jessica A. Gasser,Jessica A. Gasser,Daniel E Grinshpun,Daniel E Grinshpun,Pierre M. Jean Beltran,Namrata D. Udeshi,Mary E Matyskiela,Thomas Clayton,Marie McConkey,Kaushik Viswanathan,Alexander Tepper,Alexander Tepper,Andrew A Guirguis,Andrew A Guirguis,Andrew A Guirguis,Rob S. Sellar,Sophie Cotteret,Christophe Marzac,Véronique Saada,Stéphane de Botton,Jean-Jacques Kiladjian,Jean-Michel Cayuela,Mark Rolfe,Philip P Chamberlain,Steven A. Carr,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +30 more
TL;DR: It is found that avadomide induces CRBN-dependent ubiquitination and proteasomal degradation of ZMYM2 (ZNF198), a transcription factor involved in balanced chromosomal rearrangements with FGFR1 and FLT3 in aggressive forms of hematologic malignancies.